AI
PBYI icon

Analytic Investors’s Puma Biotechnology PBYI Stock Holding History

Analytic Investors’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-5,376
Closed -$288K – 552
2013
Q3 		$288K Buy
+5,376
New +$290K ﹤0.01% 459

Other funds holding PBYI

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Analytic Investors's PBYI Position: Q4 2013 in Review

Analytic Investors sold out of Puma Biotechnology (PBYI) in Q4 2013, closing a stake of 5,376 shares — an estimated $288K sold.

Analytic Investors first reported a position in PBYI in Q3 2013 and held it in 1 quarter. The position peaked at $288K in Q3 2013. 116 funds tracked by Wall St. Rank hold PBYI as of Q4 2013.

  • Analytic Investors reported no remaining Puma Biotechnology position as of Q4 2013 after selling out during the quarter.
  • Analytic Investors sold 5,376 Puma Biotechnology shares in Q4 2013, an estimated $288K.
  • Analytic Investors first reported a position in Puma Biotechnology in Q3 2013 and held it in 1 quarter.
  • Analytic Investors's Puma Biotechnology position peaked at $288K in Q3 2013.
  • 116 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2013.

Based on Analytic Investors's 13F filing for Q4 2013, filed 13 Feb 2014.